Welcome to our dedicated page for CARLSMED SEC filings (Ticker: CARL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Carlsmed, Inc. (Nasdaq: CARL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public medical technology issuer. Carlsmed uses its filings, including Form 8-K, to report financial results, material agreements, and capital structure changes related to its AI-enabled personalized spine surgery platform, aprevo.
Carlsmed’s Form 8-K filings referenced in its disclosures include items on quarterly financial results, where the company furnishes press releases that detail revenue, gross profit, operating expenses, net loss, cash and cash equivalents, and non-GAAP measures such as Adjusted EBITDA. These filings explain how the company reconciles Adjusted EBITDA to GAAP net loss and describe the items excluded from this non-GAAP metric. They are a primary source for understanding Carlsmed’s operating performance and financial condition over time.
Other 8-K filings describe material definitive agreements, such as amendments to the company’s loan and security agreement with Customers Bank. These filings outline the size of the term loan and non-formula revolving line of credit, interest terms, maturity dates, financial covenants, and related warrant arrangements. Modifications to warrants and credit availability are documented in these filings, giving investors insight into Carlsmed’s debt financing and obligations.
As Carlsmed continues as a public company, investors can also look to its periodic reports, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, for more detailed information on risk factors, business description, financial statements, and segment information once those documents are available. On Stock Titan, Carlsmed’s filings are updated from the SEC’s EDGAR system, and AI-powered tools can help summarize key points, highlight changes between periods, and surface items related to revenue, operating expenses, debt facilities, warrant liabilities, and non-GAAP measures. Users can also review any future Form 4 insider transaction reports and proxy statements when they are filed to understand executive equity holdings and governance matters.
Carlsmed, Inc. reports rapid 2025 growth as it scales its AI‑enabled aprevo Technology Platform for personalized spine fusion. Revenue rose to
The company remains in investment mode, with net loss widening to
The platform had 253 surgeon users as of
Carlsmed, Inc. reported rapid growth in its AI-enabled spine surgery business for 2025, with revenue rising to
Growth is being driven by new products like the aprevo® cervical system, the myaprevo® ecosystem, and first-in-human procedures for personalized spine implants. Operating expenses increased to
Carlsmed ended 2025 with
Carlsmed, Inc. reported that Chief Commercial Officer William Scott Durall acquired 44,977 shares of common stock on January 28, 2026 at a price of $0 per share. These shares relate to restricted stock units, each representing the right to receive one share of common stock.
The RSUs will vest in three equal annual installments beginning on the first anniversary of the grant date, providing Durall with equity that vests over a multi-year period as long as the vesting conditions are met.
Carlsmed, Inc. director and Chief IP Officer Niall Casey received an equity award of 44,977 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Carlsmed common stock and will vest in three equal annual installments beginning on the first anniversary of the grant date of January 28, 2026.
Following this award, Casey beneficially owned 982,562 shares of Carlsmed common stock on a direct basis, according to the filing.
Carlsmed, Inc. CEO and President Michael Cordonnier, who also serves as a director, received an equity award of 117,316 shares of common stock on January 28, 2026. These are restricted stock units, each convertible into one share, vesting in three equal annual installments starting on the first anniversary of the grant date. Following this grant, he beneficially owned 1,356,646 shares of Carlsmed common stock in direct ownership.
Carlsmed, Inc. reported an equity award to its CFO and Treasurer, Leonard Greenstein. On 01/28/2026, he received 44,977 shares of common stock at a price of $0, tied to restricted stock units that each represent one future share if vesting conditions are met.
After this grant, Greenstein beneficially owned 188,346 shares directly. The RSUs vest in three equal annual installments beginning on the first anniversary of the grant date, so the award is spread over three years rather than delivered all at once.
Carlsmed, Inc. filed a current report to disclose that it has issued a press release announcing its preliminary, unaudited revenue for the year ended December 31, 2025. The company furnished the full text of this press release as Exhibit 99.1, stating that it is incorporated by reference in the report but will not be treated as filed for liability purposes under the Exchange Act. The filing also notes that Carlsmed’s common stock trades on The Nasdaq Stock Market LLC under the symbol CARL.
Carlsmed (CARL) filed its Q3 2025 report, showing higher sales and a stronger balance sheet following its IPO. Revenue for the quarter reached $13.1 million, up from $6.6 million a year ago, while the net loss was $8.5 million versus $7.8 million last year. For the nine months, revenue was $35.3 million compared with $17.8 million in 2024, reflecting broader commercial uptake of the aprevo platform.
Cash and cash equivalents rose to $115.4 million, primarily from the July IPO of 6,700,000 shares at $15.00, which provided $93.5 million in net proceeds. All preferred stock converted into 15,245,731 common shares at closing. Debt outstanding under the Customers Bank facility was $15.6 million as of September 30, 2025. A subsequent amendment on October 29, 2025 expanded borrowing capacity, including a term loan of up to $50.0 million and a $10.0 million revolving line, capped at an aggregate $50.0 million.
Shares outstanding were 26,592,908 as of November 3, 2025. Operating expenses increased as the company invested in sales, marketing, and administration to support growth.
Carlsmed, Inc. furnished an update on its latest performance. The company announced financial results for the quarter ended September 30, 2025, via a press release furnished with a Form 8-K.
The press release is included as Exhibit 99.1. The information furnished under Item 2.02 is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference into Securities Act filings except as specifically referenced.